88 Chapter 4 Table 3. Change in Monthly Migraine Days (MMD), Monthly Headache Days (MHD), and Monthly Acute Medication Days (MAMD) for month 1 and month 2 after COVID-19 vaccination compared to the baseline month. One month is defined as 28 days. Total months of E-diary data was n=536 months from n=147 participants. Estimates 95% confidence interval P-value Monthly Migraine Days (MMD) Month 1 1.06 0.57 – 1.55 <0.001 Month 2 0.47 -0.12 – 1.06 0.117 Monthly Headache Days (MHD) Month 1 1.52 0.91 – 2.14 <0.001 Month 2 1.07 0.32 – 1.81 0.005 Monthly Acute Medication Days (MAMD) Month 1 0.72 0.33 – 1.12 <0.001 Month 2 0.50 0.03 – 0.98 0.038 Figure 2: Crude means ± SEM for migraine-related outcomes during baseline (28 days) and month 1 and month 2 following vaccination. *p≤ 0.05 in linear mixed model.
RkJQdWJsaXNoZXIy MjY0ODMw